Gaithersburg, Maryland – March 18, 2019: MaxCyte announced today that Debra K. Bowes, Chief Business Officer, CARMA™ Cell Therapy, will present “Novel mRNA-based Autologous CAR Therapies in Oncology” at two upcoming industry conferences. The 13th Annual International Partnering Conference BIO-Europe Spring® takes place March 25–27 in Vienna, Austria. The inaugural 2019 Cell & Gene Meeting on the Mediterranean will be held April 23-25 in Barcelona, Spain.
Ms. Bowes will discuss MaxCyte’s next-generation autologous CAR (chimeric antigen receptor) therapies, highlighting how MaxCyte’s novel and proprietary CARMA platform in immuno-oncology has the ability to engineer CARs with transient persistence that may mitigate off-tumor toxicity and significantly reduce the turnaround time for delivery of autologous cell therapy to patients.
The presentation dates and times for each conference follow:
13th Annual International Partnering Conference BIO-Europe Spring®
|Date:||Tuesday, March 26, 2019|
|Time:||10:45 a.m. CET|
|Category:||Cell and Gene Therapies|
2019 Cell & Gene Meeting on the Mediterranean
Date: Tuesday, April 23, 2019
Time: 2:45 p.m. CET
“Our novel CAR cell therapeutic products are engineered with the intention of reducing potential adverse events that have been evident with previous CAR technologies,” said Ms. Bowes. “This is significant, now more than ever, as we advance dosing of patients in our first clinical study with our first wholly-owned lead CAR therapeutic candidate, MCY-M11. I look forward to the opportunity to discuss our CARMA platform’s potential in a broad range of targets and cancers, including solid tumors, at the two upcoming European conferences.”
Investigators are currently evaluating the safety and effectiveness of intraperitoneal infusions of MCY-M11 in a multi-center, non-randomized, open label, dose-escalation Phase I clinical trial in individuals with ovarian cancer and peritoneal mesothelioma. More information about the study can be found at ClinicalTrials.gov.
MaxCyte is a clinical-stage global cell-based medicines and life sciences company applying its proprietary cell engineering platform to deliver the advances of cell-based medicine to patients with high unmet medical needs. MaxCyte is developing novel CARMA™ therapies for its own pipeline, with its first drug candidate in a Phase 1 clinical trial. CARMA is MaxCyte’s mRNA-based proprietary therapeutic platform for autologous cell therapy for the treatment of solid cancers. In addition, through its core business, MaxCyte leverages its Flow Electroporation® Technology to enable its biopharmaceutical partners to advance the development of innovative medicines, particularly in cell therapy. MaxCyte has placed its flow electroporation instruments worldwide, with all of the top ten global biopharmaceutical companies, has more than 70 partnered program licenses in cell therapy including more than 35 licensed for clinical use. With its robust delivery technology platform, MaxCyte helps its partners to unlock the full potential of their products. For more information, visit www.maxcyte.com
For further information, please contact:
|Doug Doerfler, Chief Executive OfficerDebra Bowes, Chief Business Officer
CARMA Cell Therapy
|+1 301 944 1660|
|US Media Relations
+1 410 299 3310